Harrow, Inc. Retained Earnings
Harrow, Inc. (HROW) had Retained Earnings of -$201.40 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-10
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$201.40M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$184.13M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$156.52M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$163.15M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$201.40M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | -$184.13M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$156.52M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | -$163.15M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$164.17M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$169.16M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$151.38M 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$158.16M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | -$153.94M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | -$147.47M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -$133.90M 10-K · filed 2025-03-27 | |
| 2023-09-30 | -$124.76M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$120.36M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | -$116.14M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$109.49M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$110.55M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | -$104.08M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$97.84M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | -$95.41M 10-K · filed 2023-03-23 | |
| 2021-09-30 | -$87.99M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$79.66M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | -$77.18M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | -$77.40M 10-K · filed 2022-03-10 | |
| 2020-09-30 | -$78.55M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | -$87.19M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$86.95M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$74.04M 10-K · filed 2021-03-08 | |
| 2019-09-30 | -$76.70M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | -$65.23M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$62.85M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | -$74.21M 10-K · filed 2020-03-13 | |
| 2018-09-30 | -$92.34M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | -$89.83M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | -$92.35M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$88.84M 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$86.06M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | -$80.37M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | -$81.86M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$76.85M 10-K · filed 2018-03-08 | |
| 2016-09-30 | -$70.75M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | -$66.90M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | -$62.26M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | -$57.76M 10-K · filed 2017-03-21 | |
| 2015-09-30 | -$52.64M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$48.69M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | -$44.96M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | -$41.87M 10-K · filed 2016-03-23 | -$41.87M 10-K · filed 2015-03-12 |
| 2014-09-30 | -$39.12M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | -$36.67M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $34.10M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$31.75M 10-K · filed 2015-03-12 | $31.70M 10-K · filed 2014-03-28 |
| 2013-09-30 | $29.90M 10-Q · filed 2013-11-06 | |
| 2013-03-31 | $25.60M 10-Q · filed 2013-05-08 | |
| 2012-06-30 | $21.40 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |